Phase Ib/II study of hydroxychloroquine in combination with chemotherapy in patients with metastatic non-small cell lung cancer (NSCLC)
Malhotra, Jabbour, Orlick et al
Cancer Treat Res Commun (2019) 21, 100158
Corrected calcium versus ionized calcium measurements for identifying hypercalcemia in patients with multiple myeloma
Buege, Do, Lee et al
Cancer Treat Res Commun (2019) 21, 100159
PM2.5 inhibits SOD1 expression by up-regulating microRNA-206 and promotes ROS accumulation and disease progression in asthmatic mice
Wang, Xu, Liu et al
Int. Immunopharmacol. (2019) 76, 105871
Suppression of NLRP3 and NF-κB signaling pathways by α-Cyperone via activating SIRT1 contributes to attenuation of LPS-induced acute lung injury in mice
Liu, Jin, Yu et al
Int. Immunopharmacol. (2019) 76, 105886
A meta-analysis of adjuvant EGFR-TKIs for patients with resected non-small cell lung cancer
Cheng, Li, Wang et al
Lung Cancer (2019) 137, 7-13
Current management of limited-stage SCLC and CONVERT trial impact: Results of the EORTC Lung Cancer Group survey
Levy, Hendriks, Le Péchoux et al
Lung Cancer (2019) 136, 145-147
Circulating microRNA-590-5p acts as a liquid biopsy marker in non-small cell lung cancer
Khandelwal, Seam, Gupta et al
Cancer Sci. (2019)
Monitoring antibody binding to T cells in a pembrolizumab-treated patient with lung adenocarcinoma on hemodialysis
Osa, Uenami, Naito et al
Thorac Cancer (2019)
Distinct initiating events underpin the immune and metabolic heterogeneity of KRAS-mutant lung adenocarcinoma
Best, Ding, Kersbergen et al
Nat Commun (2019) 10, 4190
IL-37 Attenuates Lung Fibrosis by Inducing Autophagy and Regulating TGF-β1 Production in Mice
Kim, Baek, Lee et al
J. Immunol. (2019)
Plasma Levels of Soluble PD-L1 Correlate With Tumor Regression in Patients With Lung and Gastric Cancer Treated With Immune Checkpoint Inhibitors
Ando, Hamada, Watanabe et al
Anticancer Res. (2019) 39, 5195-5201
Performance Status and Its Changes Predict Outcome for Patients With Inoperable Stage III NSCLC Undergoing Multimodal Treatment
Käsmann, Taugner, Eze et al
Anticancer Res. (2019) 39, 5077-5081
Previous Immune Checkpoint Inhibitor Treatment to Increase the Efficacy of Docetaxel and Ramucirumab Combination Chemotherapy
Harada, Takata, Mori et al
Anticancer Res. (2019) 39, 4987-4993
Brexpiprazole Reduces Survivin and Reverses EGFR Tyrosine Kinase Inhibitor Resistance in Lung and Pancreatic Cancer
Sanomachi, Suzuki, Togashi et al
Anticancer Res. (2019) 39, 4817-4828
Eribulin Suppressed Cisplatinum- and Doxorubicin-resistant Recurrent Lung Metastatic Osteosarcoma in a Patient-derived Orthotopic Xenograft Mouse Model
Kiyuna, Tome, Miyake et al
Anticancer Res. (2019) 39, 4775-4779
Dynamics of Circulating Tumor Cells Early After Targeting Therapy to Human EGFR-mutated Lung Cancers and HER2 Gene-amplified Gastric Cancers in Mice
Ito, Nakanishi, Yoshimura et al
Anticancer Res. (2019) 39, 4711-4720
Propagermanium Induces NK Cell Maturation and Tends to Prolong Overall Survival of Patients With Refractory Cancer
Kikuchi, Noguchi, Wakai et al
Anticancer Res. (2019) 39, 4687-4698
AMMECR1 Inhibits Apoptosis and Promotes Cell-cycle Progression and Proliferation of the A549 Human Lung Cancer Cell Line
Ge, Cheng, Xu et al
Anticancer Res. (2019) 39, 4637-4642
Sarcopenia as Prognostic Factor in Lung Cancer Patients: A Systematic Review and Meta-analysis
Buentzel, Heinz, Bleckmann et al
Anticancer Res. (2019) 39, 4603-4612
Critical Assessment in Routine Clinical Practice of Liquid Biopsy for EGFR Status Testing in Non-Small-Cell Lung Cancer: A Single-Laboratory Experience (LPCE, Nice, France)
Heeke, Benzaquen, Hofman et al
Clin Lung Cancer (2019)